RT Journal Article
SR Electronic
T1 WearGait-PD: An Open-Access Wearables Dataset for Gait in Parkinson’s Disease and Age-Matched Controls
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.11.24313476
DO 10.1101/2024.09.11.24313476
A1 Anderson, Anthony J.
A1 Eguren, David
A1 Gonzalez, Michael A.
A1 Khan, Naima
A1 Watkinson, Sophia
A1 Caiola, Michael
A1 Hirczy, Siegfried S
A1 Zabetian, Cyrus P.
A1 Mills, Kelly
A1 Moukheiber, Emile
A1 Moro-Velazquez, Laureano
A1 Dehak, Najim
A1 Motely, Chelsie
A1 Muir, Brittney C.
A1 Butala, Ankur
A1 Kontson, Kimberly
YR 2024
UL http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313476.abstract
AB Wearable movement sensors are powerful tools for objectively characterizing and quantifying movement. They enhance the precise characterization of gait, balance, and motor symptoms in Parkinson’s disease and related disorders, facilitating in-clinic and remote assessments, disease management, and therapeutic intervention development. Access to high-quality data from these sensors can accelerate discoveries in this clinical population. The WearGait-PD open-access dataset contains raw inertial measurement unit (IMU) and sensorized insole data from individuals with PD and age-matched controls, synchronized to a gait walkway reference system. IMU data include 3-degree of freedom (DOF) acceleration, rotational velocity, magnetic field strength, and orientation for each of 13 sensors on the participant’s body. Sensor insole data include absolute pressure from 16 sensors in each insole and 3-DOF acceleration and rotational velocity. Walkway data include 2D position and relative pressure for each active sensor during every footfall. Frame-by-frame annotation of participant actions during gait and balance tasks was incorporated using synchronized video cameras. All data were associated with demographic information and clinical evaluations (e.g., medications, DBS-status, MDS-UPDRS scores).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the US Food and Drug Administration and the Consolidated Anti-Aging Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These data were collected under the Johns Hopkins School of Medicine (JHM) IRB00234370 with an IRB Authorization Agreement (95-CDRH-2021-12-18) and VA IRB01702255 with an IRB Authorization Agreement (2023-CDRH-095), for which FDA is the relying institution.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.synapse.org/Synapse:syn52540892/wiki/623751 https://www.synapse.org/Synapse:syn52540892/wiki/623751